© 2021
In touch with the world ... at home on the High Plains
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
KJJP-FM 105.7 is currently operating at very reduced power and signal range using a back-up transmitter. This is because of complicated problems with its very old primary transmitter. Local engineers are currently working on that transmitter and consulting with the manufacturer to diagnose and fix the problems. We apologize for this disruption and service as we work as quickly as possible to restore KJPFM to full power. In the mean time you can always stream either the HPPR mix service or HPPR connect service using the player above or the HPPR app.

KU To Help Test Malaria Drug Touted By President Trump As Possible COVID-19 Treatment

Hydroxychloroquine, an anti-malaria drug not yet officially approved to fight the coronavirus, has been championed by President Trump as a possible treatment for COVID-19.
John Locher
/
Associated Press
Hydroxychloroquine, an anti-malaria drug not yet officially approved to fight the coronavirus, has been championed by President Trump as a possible treatment for COVID-19.

The University of Kansas Medical Center will take part in a nationwide clinical trial of a drug touted by President Trump as a possible treatment for COVID-19.

The hospital said it will test the effectiveness of hydroxychloroquine in preventing COVID-19 infections in health care workers, according to a KU news release.

KU said it’s one of 60 participants in the clinical trial, which will be led by the Duke Clinical Research Institute.

The drug, which is used to treat malaria and is often prescribed for people with lupus or rheumatoid arthritis, has been the subject of small, inconclusive trials in France and China.

Trump, however, has lauded the drug as a possible treatment, triggering a run on the drug.

“I feel good about it. That's all it is, just a feeling,” Trump said last month during a White House briefing about hydroxychloroquine.

In Missouri, a big jump in prescriptions for the drug prompted a joint statement three weeks ago by the Missouri Board of Pharmacy and the Missouri State Board of Registration for the Healing Arts that “this activity may lead to stockpiling of medication, inappropriate use and potential drug shortages for patients with a legitimate need.”

KU is hoping to recruit 500 health care workers, including doctors, nurses, therapists, first responders, food service workers and environmental services workers, for its clinical trial, according to the KU release.

The double-blind clinical trial, the gold standard for determining a drug’s safety and efficacy, is funded by the Patient-Centered Outcome Research Institute (PCORI), a government sponsored nonprofit that funds comparing the benefits of established medical treatments.

Dr. Mario Castro, vice chair for clinical and translational research and a pulmonologist at the University of Kansas School of Medicine, will serve as principal investigator of the KU clinical trial.

“At this point in the pandemic, hospitals are reporting that 20% of U.S. health care workers are becoming infected with COVID-19,” Castro said in a statement. “When that happens, one in five must go into quarantine and cannot take care of patients. This study is critical for safeguarding the personal health of these workers and for protecting the health care workforce at this critical time. Our hope is that this drug will decrease the risk of exposed workers developing an active COVID-19 infection.”

At least 5,400 nurses, doctors, and other health care workers in the United States have been infected by COVID-19 and dozens have died, according to a BuzzFeed News review of data reported by every state and Washington, D.C. The news outlet said the actual number is probably much higher because of inconsistent testing and tracking of the disease.

Dan Margolies is a senior reporter and editor at KCUR. You can reach him on Twitter @DanMargolies.

Copyright 2020 KMUW | NPR for Wichita

Dan was born in Brooklyn, N.Y. and moved to Kansas City with his family when he was eight years old. He majored in philosophy at Washington University in St. Louis and holds law and journalism degrees from Boston University. He has been an avid public radio listener for as long as he can remember – which these days isn’t very long… Dan has been a two-time finalist in The Gerald Loeb Awards for Distinguished Business and Financial Journalism, and has won multiple regional awards for his legal and health care coverage. Dan doesn't have any hobbies as such, but devours one to three books a week, assiduously works The New York Times Crossword puzzle Thursdays through Sundays and, for physical exercise, tries to get in a couple of rounds of racquetball per week.
Dan Margolies
In a long and varied journalism career, Dan has worked as a business reporter for the Kansas City Business Journal, The Kansas City Star and Reuters. In a previous life, he was a lawyer. He has also worked as a media insurance underwriter and project development director for a small video production firm.